Long-read full-length transcriptome sequencing reveals multilayered sex-associated isoform regulation in thyroid carcinoma

Thyroid cancer is the most common cancer of the endocrine system, the network of glands that control how our bodies use energy and grow. For decades, doctors and scientists have known that this disease behaves differently in men and women. Women are diagnosed with thyroid cancer far more often than men, and the disease sometimes follows a different course in each group. While researchers have long suspected that biology plays a role in this gap, the exact molecular reasons have remained hidden. For a long time, the standard way to study cancer was to look at genes as if they were single, static units, measuring how much of a gene was turned on or off. However, a single gene does not always produce just one product. Much like a single recipe can be adjusted to create several different dishes, a single gene can be processed in various ways to create multiple versions of a molecule called a transcript. These different versions, or isoforms, can have distinct shapes and functions, even if the total amount of the gene remains the same. Understanding these subtle variations is crucial because they can change how a cell behaves, potentially driving cancer growth or influencing how a patient responds to treatment.

A team of researchers at The Affiliated Tumor Hospital of Xinjiang Medical University set out to see if these hidden variations in transcript shapes could explain the differences between men and women with thyroid cancer. Instead of using the standard, fragmented methods of reading genetic material, they employed a newer technology called Oxford Nanopore sequencing. This advanced approach allows scientists to read entire, full-length transcripts in one go, rather than trying to piece together a puzzle from tiny, broken fragments. By applying this method to tumor samples from ten patients—four men and six women—the team created a detailed map of the full-length genetic messages present in these tumors. They were looking for patterns that would show up only when examining the specific shapes of the transcripts, rather than just the total volume of genetic activity.

The results revealed a complex landscape of differences that standard methods would have missed. While the researchers did find that some genes were more active in men than in women, the real story lay in the transcripts themselves. They identified over two thousand transcripts that were used differently between the sexes, a number nearly double the count of genes that showed different activity levels. Crucially, they found hundreds of cases where the total amount of a gene did not change at all, yet the specific versions of the transcripts being produced shifted dramatically. This suggests that the biological difference between male and female thyroid tumors is not just about how much genetic material is present, but about which specific versions of that material are being used.

To understand how these changes happened, the team looked at the specific mechanisms that create these different transcript versions. They found evidence of alternative splicing, a process where parts of a genetic message are cut and pasted together in different orders, occurring in sixty-eight different events that favored one sex over the other. They also discovered hundreds of instances where the ends of the transcripts were trimmed or extended differently, a process known as alternative polyadenylation, which can alter how stable a message is or how it is read by the cell. When the researchers combined all these layers of information—gene activity, transcript abundance, splicing patterns, and end modifications—they identified fifty-six key candidates that showed consistent changes across every level. Among these were specific long non-coding RNAs, such as SNHG5 and PTCSC2, which appeared to be central to the sex-based differences in the tumor.

The team did not stop at their small group of ten patients. To ensure these findings were not just a fluke of their specific samples, they turned to a massive, publicly available database of thyroid cancer data from over five hundred patients. When they looked at the gene activity levels in this larger group, they could not find the same sex-based differences they had seen in their own study. However, when they analyzed the specific parts of the genes that correspond to the transcript versions they had identified, the sex-based signal reappeared. This confirmed that the differences they found were real and reproducible, but that they were invisible to traditional methods that only look at the total amount of a gene. The study also compared their findings against data from normal, healthy thyroid tissue. They found that in healthy tissue, almost no genes showed sex-based differences in their total activity, except for those located directly on the sex chromosomes. This ruled out the possibility that the differences they saw in the tumors were simply a reflection of normal biological differences between men and women; instead, these changes were specific to the cancer itself.

The study concludes that the molecular basis for sex disparities in thyroid cancer is far more intricate than previously thought. It is not merely a matter of men having more or less of a certain gene than women. Instead, the cancer cells in men and women are remodeling the very identity of their genetic messages, creating different versions of transcripts that likely drive the disease in distinct ways. By using full-length sequencing to see these hidden structures, the researchers have opened a new window into understanding tumor heterogeneity. Their work suggests that to fully grasp how cancer behaves and why it affects men and women differently, scientists must look beyond simple gene counts and examine the detailed architecture of the transcripts themselves. This approach provides a clearer, more complete picture of the disease, offering new targets for future research and potentially more precise ways to understand the unique biology of thyroid cancer in each patient.